Core Viewpoint - 威胜控股 plans to sell 100% equity of 富研投资有限公司 to Harbour Equity Partners Ltd for RMB 46 million, focusing on long-term sustainable development and strategic business adjustments [1] Group 1: Transaction Details - The transaction involves the sale of 富研投资有限公司, which primarily provides smart energy solutions to specific downstream customers in North America [1] - The sale price for the equity is set at RMB 46 million [1] Group 2: Strategic Rationale - The decision to enter into the share purchase agreement is based on a careful consideration of the market and competitive environment [1] - The company aims to continue its strategic focus on the domestic market in Greater China while accelerating overseas market expansion [1] - The emphasis will be on meeting diverse and personalized demands in other overseas markets [1]

Core Viewpoint - The company is selling its 100% stake in Fuyuan Investment Co., Ltd. to Harbour Equity Partners Ltd. for RMB 46 million, as part of its long-term sustainable development strategy [1] Group 1: Transaction Details - The transaction is set to be completed on December 24, 2025 [1] - The target company primarily provides smart energy solutions to specific downstream customers in North America [1] - The target company is currently wholly owned by the company's indirect non-wholly owned subsidiary, Weisheng Energy Hong Kong [1] Group 2: Strategic Rationale - The decision to sell the target group is based on careful consideration of the market and competitive environment [1] - The company aims to continue focusing on its strategic priorities in the Greater China domestic market [1] - The company plans to accelerate its overseas market expansion, emphasizing the need to meet diverse and personalized demands in other international markets [1]

Core Viewpoint - SF Express has officially ended its collaboration with Douyin's e-commerce return service, which is described as a normal business practice as the contract naturally expired [1] Group 1: Business Operations - SF Express will not participate in the Douyin e-commerce return service for 2026, indicating a voluntary withdrawal from this market segment [1] - The return service responsibilities will be gradually taken over by other logistics providers such as JD, Zhongtong, and YTO [1] Group 2: Strategic Adjustments - The change is primarily attributed to SF Express's internal business and strategic adjustments, as the company faces growth pressures [1] - SF Express is continuing to scale back its return service operations in response to these pressures [1]

Core Viewpoint - Mannings, a well-known drugstore chain, will close all offline stores and its online mall in mainland China as part of a strategic business adjustment, while continuing its cross-border operations [1][3]. Group 1: Store Closures - Mannings will cease operations of its offline stores in mainland China on January 15, 2026, and its online official mall will stop operating on December 28, 2025 [1]. - The company currently has over 440 stores, with more than 120 in mainland China and over 320 in Hong Kong and Macau, covering 33 cities [3]. Group 2: Strategic Shift - The closure of mainland stores is part of a strategic shift towards cross-border e-commerce, leveraging its supply chain advantages from Hong Kong to cater to the cross-border shopping needs of mainland consumers [1]. - Mannings will continue its cross-border business through various platforms, including its cross-border official mall and flagship stores on Tmall, JD.com, and Pinduoduo [1]. Group 3: Consumer Sentiment - Consumer reactions to the closure have been mixed, with many expressing sadness and sharing memories associated with the brand on social media [3][4].

Core Viewpoint - Mannings, a well-known drugstore chain, will close all offline stores and its online mall in mainland China as part of a strategic business adjustment, while continuing its cross-border operations [1][2]. Group 1: Store Closures - Mannings will cease operations of its offline stores on January 15, 2026, and its online official mall will stop operating on December 28, 2025 [1]. - The Tmall flagship store, JD flagship store, and Tmall health products specialty store will close on December 26, 2025 [1]. Group 2: Strategic Shift - The closure of mainland stores is part of a strategic adjustment, indicating a shift from physical retail to cross-border e-commerce, leveraging its supply chain advantages from Hong Kong [2][3]. - Mannings will continue its cross-border business, including the cross-border official mall, Tmall flagship store, JD flagship store, and Pinduoduo flagship store [2]. Group 3: Company Background - Mannings was founded in 1972 by two pharmacists in Hong Kong and became part of the Dairy Farm Group in 1976 [3]. - The company officially entered the mainland market in 2004 [4]. - As of December 17, 2025, Mannings has over 440 stores, with more than 320 in Hong Kong and Macau, and over 120 in mainland China, covering 33 cities [6]. Group 4: Consumer Reactions - Consumer reactions to the closure have been mixed, with some expressing regret on social media, sharing memories associated with the brand [7].

Core Viewpoint - The company, Zhonghuan Environmental Protection, plans to raise up to 300 million yuan through a private placement of shares, with the funds aimed at supplementing working capital and repaying bank loans [1]. Group 1: Share Issuance Details - The share issuance price is set at 6.85 yuan per share, with a maximum of 43,795,620 shares to be issued, representing 9.51% of the company's total share capital before the issuance [1]. - The shares will be subscribed by the actual controller, Liu Yang, who has signed a conditional share subscription agreement to fully subscribe in cash [1]. - Following the issuance, Liu Yang's direct or indirect control over the company will increase to 22.68% [1]. Group 2: Change in Company Control - The company’s controlling shareholder has changed to Beijing Dingyuan, with Liu Yang becoming the actual controller [2][3]. - Prior to the transfer, the controlling shareholder was Zhang Bozhong, who held 28.05% of the shares [5]. - The share transfer involved a total of 70,541,359 shares, representing 16.53% of the total share capital, with a transfer price of approximately 8.48 yuan per share [3][5]. Group 3: Corporate Name Change - The company plans to change its name from Anhui Zhonghuan Environmental Protection Technology Co., Ltd. to Anhui Orivie Technology Co., Ltd., along with a new stock abbreviation to Zhongfu Technology [6][7]. - This name change aims to better reflect the company's current business and strategic characteristics while maintaining its core environmental protection business [6].

格隆汇11月20日丨澳博控股(00880.HK)发布公告，有关(其中包括)董事会先前有意收购十六浦娱乐场的 所在物业及决定不再在若干卫星娱乐场继续经营博彩业务("该公告")。承接董事会先前有意收购十六浦 娱乐场的所在物业，经过全面审慎的业务评估，以及对长远业务布局、商业考量及集团整体资源优先分 配的深入考虑后，澳娱综合将不会进行该收购。是次结果反映了集团审慎务实的资本规划，以及其专注 于强化核心业务以配合市场发展和集团长远发展的战略方针。 因此，于2025年11月20日，澳娱综合与十六浦娱乐集团有限公司("十六浦"，一间由澳娱综合持有51% 权益的附属公司)，相互同意及订立终止协议("终止协议")。根据上市规则第十四A章，十六浦并非本公 司的关连人士。根据终止协议，由相同订约方订立日期为2022年12月30日(经日期为2023年3月30日的补 充协议修订)的《提供服务协议》将自2025年11月29日起提前终止("终止")。于终止后，十六浦将不再于 十六浦娱乐场向澳娱综合提供服务，而十六浦娱乐场将结束营运。 ...

Financial Data and Key Metrics Changes - Assertio reported total product sales of $49.5 million for Q3 2025, up from $28.7 million in the prior year, primarily driven by the Rosedown two-quarter pull forward [13] - Adjusted EBITDA for Q3 2025 was $20.9 million, significantly up from $4.4 million in the prior year, largely due to higher Rosedown sales [16] - GAAP net income for Q3 2025 was $11.4 million, compared to a loss of $3 million in the prior year [16] Business Line Data and Key Metrics Changes - Rosedown net product sales reached $38.6 million in Q3 2025, a substantial increase from $15 million in the same quarter last year, attributed to the pull forward of sales [7] - Synthesan net product sales grew to $2.8 million in Q3 2025, up from $2.6 million in the prior year, driven by higher volume [8][13] - Indocin sales decreased to $4.8 million in Q3 2025 from $5.7 million in the prior year, reflecting impacts from generic competition [14] Market Data and Key Metrics Changes - Rosedown achieved a 43% market share in the clinic Medicare Part B segment in Q3 2025, reflecting strong demand and strategic distribution efforts [10] - The company experienced a 42% year-to-date demand growth for Rosedown compared to the same period in 2024 [10] Company Strategy and Development Direction - The company aims to maintain price stability and predictability for Rosedown while pursuing further demand and market share growth [12] - Assertio is currently reviewing and refining its strategies moving forward under new leadership, focusing on growth assets [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's potential to generate significant value for patients and shareholders, highlighting a solid balance sheet and core growth assets [6] - The company anticipates a temporary decline in cash flow due to the Rosedown sales transition but expects improvement in Q2 2026 [16] Other Important Information - Assertio has executed a long-term supply agreement with its API manufacturer, ensuring stable supply and pricing for Rosedown [11] - The company is tightening its 2025 guidance, expecting full-year product sales between $110 million and $112 million and adjusted EBITDA between $14 million and $16 million [17] Q&A Session Summary Question: Linkage between labeler code and ASP for Rosedown - Management clarified that the labeler code change is not tied to ASP and emphasized a strategy of price stability and predictability [20] Question: Comments on Indocin market performance - Management noted good market share and volume for Indocin despite competition, with some price favorability observed [21] Question: Optimizing Rosedown's promotional and reimbursement strategy - Management is currently reviewing all strategies and will provide updates as refinements are made [24] Question: Expectations for Synthesan sales acceleration - Management indicated that Synthesan is competing in a generic market with a focus on raising awareness and promoting its unique delivery mechanism [30]

Core Perspective - Johnson & Johnson (J&J) is divesting its orthopaedics business, marking a significant strategic shift that could reshape the company and the broader market for joint replacements and related products [1][4]. Company Summary - J&J's orthopaedics division was developed over decades, known for its hip and knee replacements, spinal interventions, and surgical tools, contributing steady revenue but facing rising competition and regulatory costs [2][3]. - The decision to explore strategic alternatives for the orthopaedics business aims to unlock value by allowing J&J to focus on higher-growth areas such as pharmaceuticals and digital surgery [3]. Industry Summary - The divestment may lead to changes in pricing, product support, and innovation priorities for hospitals and surgeons, while potentially benefiting patients through renewed focus and investment in the orthopaedics sector [4]. - The move could trigger further consolidation in the orthopaedics market as buyers seek scale, and it may accelerate the shift towards value-based purchasing and tech-enabled surgical solutions [4].

Core Insights - Kering Group has undergone significant business adjustments under the new CEO, Luca de Meo, including a strategic partnership with L'Oréal in the luxury beauty and health sector, involving a transaction valued at €4 billion (approximately ¥33.2 billion) [3][5] - The sale of Kering Beauté, which includes the Creed perfume brand and exclusive rights to Gucci, Bottega Veneta, and Balenciaga's beauty products, marks a shift in Kering's strategy as it focuses on core brands amidst a challenging luxury goods market [3][5][8] Group 1: Business Strategy Changes - Kering Group previously viewed its beauty business as a key growth driver, having acquired the Creed brand for approximately €3.5 billion and established a beauty division in 2021 [5][6] - The recent sale of the beauty business is seen as a cash-out strategy and a self-rescue move, allowing Kering to concentrate on its core brands [8][9] - Luca de Meo emphasized the need for immediate action to adapt to changing market demands, including reducing leverage, cutting costs, and rationalizing business operations [8][9] Group 2: Financial Performance - Kering Group's revenue declined from €20.35 billion in 2022 to €17.19 billion in 2024, with net profit dropping from €3.61 billion to €1.13 billion during the same period [10][11] - In the first half of 2025, Kering's revenue fell by 16% to €7.59 billion, and net profit decreased by 46% to €474 million [11] - The beauty business, while a growth highlight in 2024 with revenue of €323 million, only accounted for 1.9% of total revenue, insufficient to offset declines in core brands [12][13] Group 3: Brand Focus and Future Challenges - Bottega Veneta was one of the few brands to show growth, with a 4% increase in revenue to €1.71 billion in 2024, while Gucci's revenue fell significantly, impacting overall performance [12][13] - The immediate priority for Kering is to revitalize Gucci and other main brands, focusing on product innovation and customer engagement to regain market position [15][16] - The challenge for Kering's new CEO will be balancing short-term financial stability with long-term strategic goals, particularly in enhancing the brand image of Gucci [16]